University of Pittsburgh researchers have developed DeepRx, a deep-learning method for predicting anti-cancer drug sensitivity using omics data from individual tumors. Cancer is a heterogeneous disease, and precision oncology aims to identify and target tumor-specific aberrations. Traditional single-gene-based therapeutic indications (SGTI) are often inaccurate. DeepRx leverages deep learning models to transform raw omics data into features reflecting the states of cellular signaling systems, significantly improving the prediction of drug sensitivity. This approach has the potential to benefit millions of patients by expanding the application of existing anti-cancer drugs.